<a href="https://laohu8.com/S/CYCC">Cyclacel Pharmaceuticals</a> Reports Zero Revenue, Operating Loss of $5.04M for Q1 2025
Cyclacel Pharmaceuticals Inc. has released its financial results for the three months ended March 31, 2025. The company reported no revenue from clinical trial supply for the period, compared to $29,000 in the same period in 2024. Operating expenses increased to $5.036 million from $4.384 million in the previous year, driven by research and development expenses of $822,000 and general and administrative expenses of $4.214 million. The company incurred an operating loss of $5.036 million, compared to a loss of $4.355 million in the same period last year. Notably, Cyclacel recorded a gain of $4.947 million from the deconsolidation of a subsidiary. The company is focused on its clinical-stage biopharmaceutical operations, developing innovative cancer medicines targeting cell cycle, transcriptional regulation, epigenetics, and mitosis control biology. No guidance or outlook was provided.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclacel Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023296), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.